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The University of California at Los Angeles Quit Using
Drugs Intervention Trial (QUIT) aims to conduct a rando-
mized controlled trial of a primary-care based very brief
intervention protocol for reducing risky stimulant use and
drug-related harm in low-income, racially diverse primary
care patients attending safety-net clinics in the east central
Skid Row area of Los Angeles. The QUIT trial emphasizes
screening, very brief clinician advice (2-3 minutes), and
two telephone drug-use health education sessions versus
usual-care in the control group (240 patients per condi-
tion). Between February 18 and April 28, 2011, pre-visit
screening of adults in the waiting room was conducted
using a touch-screen Tablet PC. “At risk” drug use was
defined as casual, frequent, or binge use without the phy-
siological or psychological manifestations of dependence
(a score of 4 to 26 on the World Health Organization’s
Alcohol, Smoking, and Substance Involvement Screening
Test (ASSIST). A total of 920 adult patients were
approached: 89% were 40+ years old; 68% were male; 62%
were black, 21% were Latino, and 17% were white. Of
patients approached, 706 were excluded due to pregnancy,
because it was a nonprimary care visit, or because they
refused to participate. Among the 214 who completed the
ASSIST, substance use scores were none or low risk in
11% of participants, moderate risk in 42%, and depen-
dence-level in 47%. The number of participants in each
score range by substance were, respectively, tobacco 55,
101, and 58; alcohol 62, 98, and 54; cannabis 94, 77, and
43; cocaine 89, 74, and 51; methamphetamine/ampheta-
mine type stimulants 145, 45, and 23; inhalants 185, 20,
and 9; sedatives 143, 45, and 26; hallucinogens 174, 30,
and 10; and opioids 130, 54, and 30. Participants who were
older than 50 years were more likely to use tobacco, alco-
hol, cannabis, and cocaine; younger patients were more
likely to use amphetamines, inhalants, sedatives, hallucino-
gens, and opioids. Twenty-seven patients (3% of those
approached) met study criteria of past three-month risky
stimulant use. Seventy percent were homeless, and 30%
were marginally housed. In Skid Row, only 3% of patients
qualified for risky stimulant use intervention.
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